Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
In this editorial, we shed light on the key advances made in migraine genetics, their neurobiology and what the future might hold for the field.
A drug belonging to a new generation of acute migraine headache treatments, termed rimegepant, has been demonstrated to eliminate pain and reduce bothersome symptoms.
This week we look at a new migraine medicine, a rescheduling of cannabidiol for epilepsy and a successful trial for neuromyelitis optica spectrum disorder.
In this week’s round-up, we cover the latest industry news from the US FDA and the halt of an Alzheimer’s drug following a toxic reaction.
Novartis has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults.
Aimovig® (erenumab) has received a positive opinion from the CHMP for migraine, steering the way towards a marketing authorization from the EMA.
Novartis and Amgen have announced that Aimovig® has been approved by the US FDA for the preventive treatment of migraine in adults.
ALKS 5461 accepted for review following previous refusal-to-file for depression: industry news round-up
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis.
A preliminary study has revealed that a monoclonal antibody could prevent difficult-to-treat migraines in patients who have tried unsuccessfully to prevent them using other treatments.